Novo Nordisk Challenges

Insulin manufacturer Novo Nordisk will challenge a claim by the Federal Anti-Monopoly Service that it violated competition rules, Katrine Sperling, a spokeswoman for the Denmark-based company, said Monday.

“We have decided to challenge their decision in Moscow’s Court of Arbitration,” Sperling said.

If Novo Nordisk loses, the company could be fined as much as 15 percent of its Russian sales, the anti-monopoly agency said Friday. 


Read more